Regulation of cancer aggressive features in melanoma cells by microRNAs

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Greenberg, Eyal ^a,b   Hershkovitz, Liat ^a   Itzhaki, Orit ^a   Hajdu, Steven ^a   Nemlich, Yael ^a   Ortenberg, Rona ^a   Gefen, Nir ^a   Edry, Liat ^b   Modai, Shira ^b   Keisari, Yona ^b   Besser, Michal J ^a   Schachter, Jacob ^a   Shomron, Noam ^b   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 17 5P; MICRORNA 184; MICRORNA 204; MICRORNA 31; MICRORNA 34A; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PATHOGENESIS; PHENOTYPE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOASSAY; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICE; MICRORNAS; NEOPLASM INVASIVENESS; PHENOTYPE;

EID: 79955568605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018936     Document Type: Article

References (50)

1. Gloster HM Jr, Brodland DG, (1996) The epidemiology of skin cancer. Dermatol Surg 22: 217-226.
2. Melnikova VO, Bar-Eli M, (2008) Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 7: 997-1003.
3. Bennett DC, (2008) How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21: 27-38.
4. Hendrix MJ, Seftor EA, Hess AR, Seftor RE, (2003) Molecular plasticity of human melanoma cells. Oncogene 22: 3070-3075.
5. Frenkel S, Barzel I, Levy J, Lin AY, Bartsch DU, et al. (2008) Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond) 22: 948-952.
6. Sun B, Zhang S, Zhang D, Du J, Guo H, et al. (2006) pp. 693-698 Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma.
7. Li M, Gu Y, Zhang Z, Zhang S, Zhang D, et al. (2010) Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16: 259-266.
8. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, et al. (2010) Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12: 637-649.
9. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
10. Ma L, Weinberg RA, (2008) MicroRNAs in malignant progression. Cell Cycle 7: 570-572.
11. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158.
12. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
13. Garzon R, Calin GA, Croce CM, (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167-179.
14. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
15. Klein U, Lia M, Crespo M, Siegel R, Shen Q, et al. (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
16. Yan D, Zhou X, Chen X, Hu DN, Dong XD, et al. (2009) MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 50: 1559-1565.
17. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, et al. (2010) Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 285: 22809-22817.
18. Mu P, Han YC, Betel D, Yao E, Squatrito M, et al. (2009) Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806-2811.
19. Mueller DW, Rehli M, Bosserhoff AK, (2009) miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 129: 1740-1751.
20. Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, et al. (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 130: 2062-2070.
21. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, et al. (2010) Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 8: 27.
22. Segura MF, Belitskaya-Levy I, Rose AE, Zakrzewski J, Gaziel A, et al. (2010) Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 16: 1577-1586.
23. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, et al. (2010) MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 176: 2520-2529.
24. Muller DW, Bosserhoff AK, (2008) Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27: 6698-6706.
25. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, et al. (2010) Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 40: 841-849.
26. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, et al. (2010) The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 5: e13779.
27. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 106: 1814-1819.
28. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, et al. (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68: 2745-2754.
29. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, et al. (1991) Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47: 227-237.
30. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
31. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, et al. (2009) DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res 37: W273-276.
32. Chen J, Bardes EE, Aronow BJ, Jegga AG, (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37: W305-311.
33. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046.
34. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA, (2010) Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 70: 5147-5154.
35. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, et al. (2010) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120: 1298-1309.
36. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, et al. (2010) miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 70: 1635-1644.
37. Hermeking H, (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
38. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, et al. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 70: 1524-1533.
39. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9: 83.
40. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14: 2588-2592.
41. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, et al. (2010) Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 6: e1000730.
42. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, et al. (2010) MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 29: 4971-4979.
43. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, et al. (2009) MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 4: e6677.
44. Nachmani D, Lankry D, Wolf DG, Mandelboim O, (2010) The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol 11: 806-813.
45. Chen Y, Zhu X, Zhang X, Liu B, Huang L, (2010) Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy. Mol Ther 18: 1650-1656.
46. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
47. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, et al. (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16: 2646-2655.
48. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, et al. (1999) Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry. Am J Pathol 155: 739-752.
49. Arganda-Carreras I, Fernandez-Gonzalez R, Munoz-Barrutia A, Ortiz-De-Solorzano C, (2010) 3D reconstruction of histological sections: Application to mammary gland tissue. Microsc Res Tech.
50. Abramoff MD, Magelhaes PJ, Ram SJ, (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.